<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">IWASA, SATORU</style></author><author><style face="normal" font="default" size="100%">YAMADA, YASUHIDE</style></author><author><style face="normal" font="default" size="100%">KATO, KEN</style></author><author><style face="normal" font="default" size="100%">GOTO, AYUMU</style></author><author><style face="normal" font="default" size="100%">HONMA, YOSHITAKA</style></author><author><style face="normal" font="default" size="100%">HAMAGUCHI, TETSUYA</style></author><author><style face="normal" font="default" size="100%">SHIMADA, YASUHIRO</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Long-term Results of a Phase II Study of S-1 plus Irinotecan in Metastatic Colorectal Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-09-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">4157-4161</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><issue><style face="normal" font="default" size="100%">9</style></issue><abstract><style  face="normal" font="default" size="100%">Aim: The current study aimed to assess the long-term efficacy of combination therapy with oral S-1, a fluoropyrimidine prodrug, plus irinotecan in previously untreated patients with metastatic colorectal cancer. Patients and Methods: Between April 2004 and February 2005, 41 patients with previously untreated advanced or recurrent colorectal cancer were enrolled in the study. Chemotherapy consisted of oral administration in S-1 at 40 mg/m2 twice daily on days 1 to 14 and intravenous infusion of irinotecan at 150 mg/m2 on day 1 in a 21-day cycle. Results: The median patient follow-up was 78.0 months. The median survival time was 23.7 months, and the 2-year survival rate was 50%. The median time to tumor progression was 8.3 months. Conclusion: The results of this long-term update confirmed that first-line combination therapy with oral S-1 plus irinotecan was effective in patients with metastatic colorectal cancer.</style></abstract></record></records></xml>